Tag: Eczema
FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis
Approval is for new, first-line biologic treatment of eczema that is not well controlled with topicals in people 12 years and older
Link Between n-3 LCPUFA, Eczema Varies by Maternal COX1 Genotype
Risk for AD was lower in the n-3 LCPUFA versus placebo group among mothers with the TT genotype
Dietary Vitamin E May Be Protective Against Atopic Dermatitis
Vitamin C, retinol, and carotene are not causally tied to atopic dermatitis
Dupilumab Maintains Its Effectiveness Up to Five Years in Patients With Eczema
23.8 percent of patients discontinued dupilumab, with adverse events and ineffectiveness the most common reasons
Gen Z Perceives Atopic Dermatitis to Be More Severe
Perceived severity higher among Gen Z compared with millennial patients
Atopic Dermatitis Has Large Impact on Sexual Function Among Women
About half of women considered that atopic dermatitis may influence their gestational desire
FDA Approves Zoryve for Atopic Dermatitis
The once-daily, nonsteroidal cream is approved for adults and children 6 years and older
Lebrikizumab Tied to Sustained Atopic Dermatitis Treatment Effect
Findings seen despite negligible remaining lebrikizumab serum concentrations following treatment withdrawal
1.5 Percent Ruxolitinib Cream Safe, Effective for Teens With Eczema
Ruxolitinib cream well tolerated, and disease control maintained over a year with as-needed use
AAD: Lebrikizumab Shows Efficacy in Skin-of-Color Patients With Atopic Dermatitis
Among patients with atopic dermatitis and self-reported race other than White, 68.3 percent achieved EASI 75 at week 16
